Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Coagulation Stories

2014-02-04 20:22:49

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vgwhc9/new_oral) has announced the addition of the "Concise Analysis of the International New Oral Anticoagulants Markets" [http://www.researchandmarkets.com/research/vgwhc9/new_oral ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Anticoagulants decrease the ability of the blood to create harmful blood clots that can...

2014-02-04 20:22:36

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxcwmp/coagulation) has announced the addition of the "Concise Analysis of the International Coagulation Diagnostic Testing Markets" [http://www.researchandmarkets.com/research/qxcwmp/coagulation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Coagulation testing, which encompasses both laboratory and point of care...

2014-01-24 23:20:30

Researchers say a new biomarker could help clinicians determine which mesothelioma patients are good candidates for surgery. Raleigh, NC (PRWEB) January 24, 2014 A new article published in the British Journal of Cancer and reported by Surviving Mesothelioma suggests that a glycoprotein called fibrinogen can help predict survival in patients with malignant mesothelioma. Fibrinogen is a soluble glycoprotein found in blood plasma and important for clotting. To test its relationship to...

2013-12-23 16:23:07

PLAINSBORO, N.J., Dec. 23, 2013 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved TRETTEN(®) (Coagulation Factor XIII A-Subunit [Recombinant]) for the routine prophylaxis of bleeding in people with congenital factor XIII (FXIII) A-subunit deficiency, a serious, rare bleeding disorder with limited treatment options. TRETTEN(®) is the only recombinant treatment for congenital FXIII A-subunit deficiency. TRETTEN(®) was proven safe and...

2013-12-13 20:22:10

New Kcentra Label Includes Urgent Reversal of Warfarin in an Emergency Surgery Setting KING OF PRUSSIA, Pa., Dec. 13, 2013 /PRNewswire/ -- CSL Behring today announced that Kcentra(®) (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication -- urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or...

2013-12-03 08:31:26

Full article: http://bit.ly/EpiVax_Biotest DREIEICH, Germany and PROVIDENCE, R.I., Dec. 3, 2013 /PRNewswire/ -- Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by...

2013-11-28 23:21:18

Researchers say that treatment may be an effective reversal agent in life-threatening bleeding cases. Resource4thePeople national network of attorneys continue to offer consumers affected by allegations free consultations over compensation rights. San Diego, CA (PRWEB) November 28, 2013 http://www.resource4thepeople.com/defectivedrugs/pradaxa-lawsuits.html Resource4thePeople announced today its latest consumer update over allegations that the popular blood thinner Pradaxa (dabigatran)...

2013-11-19 12:10:08

Abstract 17765 (Room C140) For the first time, an antidote developed specifically for dabigatran successfully reversed the effects of the anti-clotting medication in healthy volunteers, according to research presented at the American Heart Association's Scientific Sessions 2013. New oral anti-clotting medications such as dabigatran (Pradaxa) are easier to take than warfarin. However, up until now, there have been no specific antidotes available to reverse the effects of these new...

2013-11-19 08:27:04

DUBLIN, Nov. 19, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/p7lggz/coagulation) has announced the addition of the "Global Coagulation Self-Testing Devices, Markets, Players and Prospects Report 2013" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The ability of patients to self-monitor is deemed to be a critical tool in reducing the pathological effects of difficult-to-control disease factors. For the millions...

2013-11-13 23:28:37

Thomas Jefferson University researchers discover a difference in platelet biology in people of African versus European descent. The findings could have implications for the treatment of heart disease. Philadelphia, PA (PRWEB) November 13, 2013 Thomas Jefferson University researchers have discovered that the formation of blood clots follows a different molecular route in African Americans versus European Americans, providing a new understanding of the effects of race on heart disease. The...